Stay updated with breaking news from David Mehalick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP – Get Free Report) CEO David Mehalick purchased 20,004 shares of the business’s stock in a transaction on Monday, January 8th. The shares were acquired at an average price of $0.66 per share, for a total transaction of $13,202.64. Following the completion of the purchase, the chief executive officer now […]
The company's shares rose 10% after it announced plans to acquire a cell therapy in phase one clinical trials.
/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today...
/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company"), a biopharmaceutical company developing innovative cell therapy platforms...
/PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC PINK: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...